RxDoctor Payments DataLook up a doctor →

Jean Hoffman-Censits, MD

Medical Oncology · Baltimore, MDNPI 1245480607

Payments from drug & device makers

$5,698,092in general payments, 2019–2025

Across 382 payments — averaging $14,916 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$4.5M
  • Daiichi Sankyo Inc.$270K
  • Daiichi Sankyo Company LTD$269K
  • Pfizer$180K
  • Genentech, Inc.$165K
  • Ares Trading SA$106K
  • plus $215K from 8 others
$20,117in research payments, 2019–2025

Across 18 payments — averaging $1117.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$16K
  • F. Hoffmann-la Roche AG$4K

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,698,092 in reported general payments places this provider in the 95th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$101,520
Medicare patients
181
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →